Search Results "#XLH"

Blogs

arrow_forward View More Results
X-Linked Hypophosphatemia XLH Treatment Market: How Is Burosumab Becoming the Fastest-Growing Targeted Therapy Replacing Conventional Management?
Posted by Surbhi 3 hours, 20 minutes ago   public
Burosumab for X-linked hypophosphatemia — the anti-FGF23 monoclonal antibody subcutaneous injection for phosphate-wasting rickets and osteomalacia representing the fastest-growing targeted therap...
arrow_forward